Mecamylamine warnings: Difference between revisions
(Created page with "__NOTOC__ {{Mecamylamine}} {{CMG}}; {{AE}} {{AK}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VECAMYL (MECAMYLAMINE HYDROCHLORIDE) TABLET...") |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AK}} | {{CMG}}; {{AE}} {{AK}} | ||
==WARNINGS== | |||
Mecamylamine, a secondary amine, readily penetrates into the brain and thus may produce central nervous system effects. Tremor, choreiform movements, mental aberrations, and [[convulsions ]]may occur rarely. These have occurred most often when large doses of Mecamylamine HCl were used, especially in patients with cerebral or renal insufficiency. | |||
When ganglion blockers or other potent [[antihypertensive ]]drugs are discontinued suddenly, hypertensive levels return. In patients with [[malignant hypertension]] and others, this may occur abruptly and may cause fatal cerebral vascular accidents or acute [[congestive heart failure]]. When Mecamylamine HCl is withdrawn, this should be done gradually and other antihypertensive therapy usually must be substituted. On the other hand, the effects of Mecamylamine HCl sometimes may last from hours to days after therapy is discontinued.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VECAMYL (MECAMYLAMINE HYDROCHLORIDE) TABLET [MANCHESTER PHARMACEUTICALS] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c6822ce4-e741-4366-b72a-5f5146354f97 | publisher = | date = | accessdate = 10 March 2014 }}</ref> | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VECAMYL (MECAMYLAMINE HYDROCHLORIDE) TABLET [MANCHESTER PHARMACEUTICALS] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c6822ce4-e741-4366-b72a-5f5146354f97 | publisher = | date = | accessdate = 10 March 2014 }}</ref> | |||
==References== | ==References== | ||
Revision as of 14:41, 10 March 2014
| Mecamylamine |
|---|
| Mecamylamine tablet®, Vecamyl® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Patient Counseling Information |
| Labels and Packages |
| Clinical Trials on Mecamylamine |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
WARNINGS
Mecamylamine, a secondary amine, readily penetrates into the brain and thus may produce central nervous system effects. Tremor, choreiform movements, mental aberrations, and convulsions may occur rarely. These have occurred most often when large doses of Mecamylamine HCl were used, especially in patients with cerebral or renal insufficiency.
When ganglion blockers or other potent antihypertensive drugs are discontinued suddenly, hypertensive levels return. In patients with malignant hypertension and others, this may occur abruptly and may cause fatal cerebral vascular accidents or acute congestive heart failure. When Mecamylamine HCl is withdrawn, this should be done gradually and other antihypertensive therapy usually must be substituted. On the other hand, the effects of Mecamylamine HCl sometimes may last from hours to days after therapy is discontinued.[1]
References
- ↑ "VECAMYL (MECAMYLAMINE HYDROCHLORIDE) TABLET [MANCHESTER PHARMACEUTICALS]". Retrieved 10 March 2014.